International Photographic Classification and Grading System for Myopic Maculopathy
Kyoko Ohno-Matsui, Ryo Kawasaki, Jost B Jonas, Chui Ming Gemmy Cheung, Seang-Mei Saw, Virginie JM Verhoeven, Caroline CW Klaver, Muka Moriyama, Kosei Shinohara, Yumiko Kawasaki, Mai Yamazaki, Stacy Meuer, Tatsuro Ishibashi, Miho Yasuda, Hidetoshi Yamashita, Akira Sugano, Jie Jin Wang, Paul Mitchell, Tien Yin Wong
AMERICAN JOURNAL OF OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2015
PURPOSE: To develop a classification and grading system for myopic maculopathy. DESIGN: Development and evaluation of a classification system for myopic maculopathy based on observational case series. METHODS: A comprehensive set of myopic macular lesions was defined via literature review and through consensus meetings among retinal specialists and clinician scientists. A classification of myopic maculopathy was formulated based on fundus photographs and a modified Delphi process and consensus. Inter- and intraobserver reproducibility, assessed as agreement (%) and weighted kappa values, were evaluated. One hundred retinal photographs with myopia and myopic macular lesions were selected from..View full abstract
Awarded by Japanese Society for Promotion of Science in Tokyo, Japan
Awarded by Chief Scientist Office
Awarded by Grants-in-Aid for Scientific Research
Tien Y. Wong is a consultant for Novartis Pharma (Basel, Switzerland) and Bayer (Leyerkusen, Germany); Kyoko Ohno-Matsui is a consultant for Bayer (Leverkusen, Germany); Ryo Kawasaki is a consultant for Office Future Inc (Tokyo, Japan); Jost B. Jonas is a consultant for Allergan Inc (Irvine, California), Merck Sharp & Dohme Co, Inc (Munchen, Germany), Alimera Co (Alpharetta, Georgia), Boehringer Ingelheim Co (Ingelheim, Germany), and Sanofi Co (Frankfurt, Germany) and is a patent holder with CellMed AG (Alzenau, Germany); Ryo Kawasaki had support for travel for the meeting of the present study from Novartis Pharma (Basel, Switzerland). Kyoko Ohno-Matsui has obtained research funding from the Japanese Society for Promotion of Science in Tokyo, Japan (22390322 and 25670729). Kyoko Ohno-Matsui and Ryo Kawasaki have obtained research funding from Novartis Pharma (Basel, Switzerland). The funding source had no influence on the interpretation or publication of the study.